RETRACTED ARTICLE: Oncogenic targeting of BRM drives malignancy through C/EBPβ-dependent induction of α5 integrin (Oncogene, (2014), 33, 19, (2441-2453), 10.1038/onc.2013.220);Oncogenic targeting of BRM drives malignancy through C/EBPβ-dependent induction of '5 integrin

Oncogene

Volumn 33, Issue 19, 2014, Pages 2441-2453

  Damiano, L ^a   Stewart, K M ^a   Cohet, N ^b   Mouw, J K ^a   Lakins, J N ^a   Debnath, J ^a   Reisman, D ^c   Nickerson, J A ^b   Imbalzano, A N ^b   Weaver, V M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

'5 integrin; Brahma; breast cancer; c Myc; C EBP ; ECM cell interactions

Indexed keywords

ALPHA2 INTEGRIN; ALPHA4 INTEGRIN; ALPHA5 INTEGRIN; BRM PROTEIN; CASPASE 3; CCAAT ENHANCER BINDING PROTEIN BETA; FIBRONECTIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN SWI; TRANSCRIPTION FACTOR SNF; VERY LATE ACTIVATION ANTIGEN 5;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOGENESIS; BREAST EPITHELIUM; CELL GROWTH; CELL SURVIVAL; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONTROLLED STUDY; FEMALE; GENE ACTIVATION; HUMAN; HUMAN CELL; IN VIVO STUDY; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; ONCOGENE C MYC; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TRANSCRIPTION TERMINATION;

BREAST NEOPLASMS; CCAAT-ENHANCER-BINDING PROTEIN-BETA; CELL ADHESION; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CHROMATIN IMMUNOPRECIPITATION; EPITHELIAL CELLS; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; INTEGRIN ALPHA5; REAL-TIME POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 84900420642     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/s41388-024-02964-y     Document Type: Erratum

References (58)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
2. Acharyya S, Oskarsson T, Vanharanta S, Malladi S, Kim J, Morris PG et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 2012; 150: 165-178.
3. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009; 139: 891-906.
4. Erez N, Truitt M, Olson P, Arron ST, Hanahan D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell 2010; 17: 135-147.
5. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012; 21: 309-322.
6. Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 2012; 196: 395-406.
7. Pylayeva Y, Gillen KM, Gerald W, Beggs HE, Reichardt LF, Giancotti FG. Ras-and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling. J Clin Invest 2009; 119: 252-266.
8. Cabodi S, Tinnirello A, Di Stefano P, Bisaro B, Ambrosino E, Castellano I et al. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis. Cancer Res 2006; 66: 4672-4680.
9. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010; 10: 9-22.
10. Weaver VM, Petersen OW, Wang F, Larabell CA, Briand P, Damsky C et al. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol 1997; 137: 231-245.
11. Lahlou H, Sanguin-Gendreau V, Zuo D, Cardiff RD, McLean GW, Frame MC et al. Mammary epithelial-specific disruption of the focal adhesion kinase blocks mammary tumor progression. Proc Natl Acad Sci USA 2007; 104: 20302-20307.
12. Guo W, Pylayeva Y, Pepe A, Yoshioka T, Muller WJ, Inghirami G et al. Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. Cell 2006; 126: 489-502.
13. Provenzano PP, Inman DR, Eliceiri KW, Beggs HE, Keely PJ. Mammary epithelial-specific disruption of focal adhesion kinase retards tumor formation and metastasis in a transgenic mouse model of human breast cancer. Am J Pathol 2008; 173: 1551-1565.
14. White DE, Kurpios NA, Zuo D, Hassell JA, Blaess S, Mueller U et al. Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell 2004; 6: 159-170.
15. Huck L, Pontier SM, Zuo DM, Muller WJ. beta1-integrin is dispensable for the induction of ErbB2 mammary tumors but plays a critical role in the metastatic phase of tumor progression. Proc Natl Acad Sci USA 2010; 107: 15559-15564.
16. Yao ES, Zhang H, Chen YY, Lee B, Chew K, Moore D et al. Increased beta1 integrin is associated with decreased survival in invasive breast cancer. Cancer Res 2007; 67: 659-664.
17. Dingemans AM, van den Boogaart V, Vosse BA, van Suylen RJ, Griffioen AW, Thijssen VL. Integrin expression profiling identifies integrin alpha5 and beta1 as prognostic factors in early stage non-small cell lung cancer. Mol Cancer 2010; 9: 152.
18. Nam JM, Onodera Y, Bissell MJ, Park CC. Breast cancer cells in three-dimensional culture display an enhanced radioresponse after coordinate targeting of integrin alpha5beta1 and fibronectin. Cancer Res 2010; 70: 5238-5248.
19. Yu M, Ting DT, Stott SL, Wittner BS, Ozsolak F, Paul S et al. RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature 2012; 487: 510-513.
20. Maschler S, Wirl G, Spring H, Bredow DV, Sordat I, Beug H et al. Tumor cell invasiveness correlates with changes in integrin expression and localization. Oncogene 2005; 24: 2032-2041.
21. Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szasz AM, Wang ZC et al. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 2009; 137: 1032-1046.
22. Tabaries S, Dong Z, Annis MG, Omeroglu A, Pepin F, Ouellet V et al. Claudin-2 is selectively enriched in and promotes the formation of breast cancer liver metastases through engagement of integrin complexes. Oncogene 2011; 30: 1318-1328.
23. Haenssen KK, Caldwell SA, Shahriari KS, Jackson SR, Whelan KA, Klein-Szanto AJ et al. ErbB2 requires integrin alpha5 for anoikis resistance via Src regulation of receptor activity in human mammary epithelial cells. J Cell Sci 2010; 123: 1373-1382.
24. Park J, Song SH, Kim TY, Choi MC, Jong HS, Lee JW et al. Aberrant methylation of integrin alpha4 gene in human gastric cancer cells. Oncogene 2004; 23: 3474-3480.
25. Yang X, Pursell B, Lu S, Chang TK, Mercurio AM. Regulation of beta 4-integrin expression by epigenetic modifications in the mammary gland and during the epithelial-to-mesenchymal transition. J Cell Sci 2009; 122: 2473-2480.
26. Wilson BG, Roberts CW. SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer 2011; 11: 481-492.
27. Reisman D, Glaros S, Thompson EA. The SWI/SNF complex and cancer. Oncogene 2009; 28: 1653-1668.
28. Hill DA, Chiosea S, Jamaluddin S, Roy K, Fischer AH, Boyd DD et al. Inducible changes in cell size and attachment area due to expression of a mutant SWI/SNF chromatin remodeling enzyme. J Cell Sci 2004; 117: 5847-5854.
29. Reisman DN, Sciarrotta J, Wang W, Funkhouser WK, Weissman BE. Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis. Cancer Res 2003; 63: 560-566.
30. Liu G, Gramling S, Munoz D, Cheng D, Azad AK, Mirshams M et al. Two novel BRM insertion promoter sequence variants are associated with loss of BRM expression and lung cancer risk. Oncogene 2011; 30: 3295-3304.
31. Bock VL, Lyons JG, Huang XX, Jones AM, McDonald LA, Scolyer RA et al. BRM and BRG1 subunits of the SWI/SNF chromatin remodelling complex are down-regulated upon progression of benign skin lesions into invasive tumours. Br J Dermatol 2011; 164: 1221-1227.
32. Yamamichi N, Inada K, Ichinose M, Yamamichi-Nishina M, Mizutani T, Watanabe H et al. Frequent loss of Brm expression in gastric cancer correlates with histologic features and differentiation state. Cancer Res 2007; 67: 10727-10735.
33. Shen H, Powers N, Saini N, Comstock CE, Sharma A, Weaver K et al. The SWI/SNF ATPase Brm is a gatekeeper of proliferative control in prostate cancer. Cancer Res 2008; 68: 10154-10162.
34. Dawson PJ, Wolman SR, Tait L, Heppner GH, Miller FR. MCF10AT: a model for the evolution of cancer from proliferative breast disease. Am J Pathol 1996; 148: 313-319.
35. Lock R, Roy S, Kenific CM, Su JS, Salas E, Ronen SM et al. Autophagy facilitates glycolysis during Ras-mediated oncogenic transformation. Mol Biol Cell 2011; 22: 165-178.
36. Kyriakis JM, App H, Zhang XF, Banerjee P, Brautigan DL, Rapp UR et al. Raf-1 activates MAP kinase-kinase. Nature 1992; 358: 417-421.
37. Adeyinka A, Nui Y, Cherlet T, Snell L, Watson PH, Murphy LC. Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression. Clin Cancer Res 2002; 8: 1747-1753.
38. Muchardt C, Bourachot B, Reyes JC, Yaniv M. ras transformation is associated with decreased expression of the brm/SNF2alpha ATPase from the mammalian SWI-SNF complex. EMBO J 1998; 17: 223-231.
39. Williams CM, Engler AJ, Slone RD, Galante LL, Schwarzbauer JE. Fibronectin expression modulates mammary epithelial cell proliferation during acinar differentiation. Cancer Res 2008; 68: 3185-3192.
40. Kwon H, Imbalzano AN, Khavari PA, Kingston RE, Green MR. Nucleosome disruption and enhancement of activator binding by a human SW1/SNF complex. Nature 1994; 370: 477-481.
41. Khavari PA, Peterson CL, Tamkun JW, Mendel DB, Crabtree GR. BRG1 contains a conserved domain of the SWI2/SNF2 family necessary for normal mitotic growth and transcription. Nature 1993; 366: 170-174.
42. Kowenz-Leutz E, Leutz A. A C/EBP beta isoform recruits the SWI/SNF complex to activate myeloid genes. Mol Cell 1999; 4: 735-743.
43. Nakajima T, Kinoshita S, Sasagawa T, Sasaki K, Naruto M, Kishimoto T et al. Phosphorylation at threonine-235 by a ras-dependent mitogen-activated protein kinase cascade is essential for transcription factor NF-IL6. Proc Natl Acad Sci USA 1993; 90: 2207-2211.
44. Corbi AL, Jensen UB, Watt FM. The alpha2 and alpha5 integrin genes: identification of transcription factors that regulate promoter activity in epidermal kera-tinocytes. FEBS Lett 2000; 474: 201-207.
45. Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 2004; 5: 816-826.
46. Bochar DA, Wang L, Beniya H, Kinev A, Xue Y, Lane WS et al. BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer. Cell 2000; 102: 257-265.
47. Reisman DN, Strobeck MW, Betz BL, Sciariotta J, Funkhouser Jr W, Murchardt C et al. Concomitant down-regulation of BRM and BRG1 in human tumor cell lines: differential effects on RB-mediated growth arrest vs CD44 expression. Oncogene 2002; 21: 1196-1207.
48. Lee D, Kim JW, Seo T, Hwang SG, Choi EJ, Choe J. SWI/SNF complex interacts with tumor suppressor p53 and is necessary for the activation of p53-mediated transcription. J Biol Chem 2002; 277: 22330-22337.
49. Sun A, Tawfik O, Gayed B, Thrasher JB, Hoestje S, Li C et al. Aberrant expression of SWI/SNF catalytic subunits BRG1/BRM is associated with tumor development and increased invasiveness in prostate cancers. Prostate 2007; 67: 203-213.
50. Glaros S, Cirrincione GM, Muchardt C, Kleer CG, Michael CW, Reisman D. The reversible epigenetic silencing of BRM: implications for clinical targeted therapy. Oncogene 2007; 26: 7058-7066.
51. Herkert B, Eilers M. Transcriptional repression: the dark side of myc. Genes Cancer 2010; 1: 580-586.
52. Gramling S, Rogers C, Liu G, Reisman D. Pharmacologic reversal of epigenetic silencing of the anticancer protein BRM: a novel targeted treatment strategy. Oncogene 2011; 30: 3289-3294.
53. Kahali B, Gramling SJB, Marquez SB, Thompson K, Lu L, Reisman D. Identifying targets for the restoration and reactivation of BRM. Oncogene 2014; 33: 653-664.
54. Grimm SL, Rosen JM. The role of C/EBPbeta in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia 2003; 8: 191-204.
55. Zahnow CA, Younes P, Laucirica R, Rosen JM. Overexpression of C/EBPbeta-LIP, a naturally occurring, dominant-negative transcription factor, in human breast cancer. J Natl Cancer Inst 1997; 89: 1887-1891.
56. Paszek MJ, Zahir N, Johnson KR, Lakins JN, Rozenberg GI, Gefen A et al. Tensional homeostasis and the malignant phenotype. Cancer Cell 2005; 8: 241-254.
57. Gilbert PM, Mouw JK, Unger MA, Lakins JN, Gbegnon MK, Clemmer VB et al. HOXA9 regulates BRCA1 expression to modulate human breast tumor phenotype. J Clin Invest 2010; 120: 1535-1550.
58. Cohet N, Stewart KM, Mudhasani R, Asirvatham AJ, Mallappa C, Imbalzano KM et al. SWI/SNF chromatin remodeling enzyme ATPases promote cell proliferation in normal mammary epithelial cells. J Cell Physiol 2010; 223: 667-678.